
 <p style="text-align: center;">Oregon Health & Science University Hospital and Clinics Provider's Orders</p> <div style="display: flex; align-items: center;"> <div style="writing-mode: vertical-rl; transform: rotate(180deg); font-size: small; margin-right: 5px;">PO7071</div>  </div> <p style="text-align: center;">ADULT AMBULATORY INFUSION ORDER Avalglucosidase Alfa (NEXVIAZYME) Infusion Page 1 of 3</p>	<p>ACCOUNT NO. _____</p> <p>MED. REC. NO. _____</p> <p>NAME _____</p> <p>BIRTHDATE _____</p> <p style="text-align: right; font-size: small;"><i>Patient Identification</i></p>
ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE.	

Weight: _____ kg Height: _____ cm

Allergies: _____

Diagnosis Code: _____

Treatment Start Date: _____ Patient to follow up with provider on date: _____

****This plan will expire after 365 days at which time a new order will need to be placed****

GUIDELINES FOR ORDERING

1. Send **FACE SHEET and H&P or most recent chart note.**
2. Life-threatening hypersensitivity reactions, including anaphylaxis, and severe infusion-associated reactions (IARs) have occurred in some patients during and after avalglucosidase alfa infusions. Patients with an acute underlying illness at the time of infusion may be at greater risk for IARs. Patients with advanced Pompe disease may have compromised cardiac and respiratory function, which may predispose them to a higher risk of severe complications from IARs. Inform patients of the signs and symptoms of anaphylaxis, hypersensitivity reactions, and IARs and have them seek immediate medical care should signs and symptoms occur.

LABS:

- CK, Plasma, ONCE, every 8 weeks
- Liver set (AST, ALT, BILI TOTAL, BILI DIRECT, ALK PHOS, ALB, PROT TOTAL), ONCE, every 8 weeks
- Hex4, Urine, ONCE, every 8 weeks
- Anti-Avalglucosidase Alfa (NEXVIAZYME) antibody to Labcorp-Sanofi Genzyme, ONCE, every 8 weeks

NURSING ORDERS:

1. Vital signs at baseline, prior to each infusion rate increase, and following infusion. Observe patient for 15 minutes post-infusion.
2. Actual Body Weight ≥30 kg: Avalglucosidase alfa (NEXVIAZYME) 20 mg/kg will be administered in a step-wise manner, beginning at an initial rate of 1 mg/kg/hr and increasing by 2 mg/kg/hr every 30 minutes (if there are no signs of infusion-associated reactions (IARs), until a maximum rate of 7 mg/kg/hr is reached.
 - a. Initial and Subsequent Infusions-DO NOT PRE-PROGRAM PUMP FOR AUTOMATIC TITRATIONS!
 - Step 1: 1 mg/kg/hr (0.25 mL/kg/hr) administered over 30 mins - If no signs of IARs, go to next step
 - Step 2: 3 mg/kg/hr (0.75 mL/kg/hr) administered over 30 mins - If no signs of IARs, go to next step
 - Step 3: 5 mg/kg/hr (1.25 mL/kg/hr) administered over 30 mins - If no signs of IARs, go to next step
 - Step 4: 7 mg/kg/hr (1.75 mL/kg/hr) administered over 30 mins - If no signs of IARs, complete infusion at this rate
3. Follow facility policies and/or protocols for vascular access maintenance with appropriate flush solution, declotting (alteplase), and/or dressing changes.



Oregon Health & Science University
Hospital and Clinics Provider's Orders

ADULT AMBULATORY INFUSION ORDER
**Avalglucosidase Alfa
(NEXVIAZYME) Infusion**

Page 2 of 3

ACCOUNT NO.
MED. REC. NO.
NAME
BIRTHDATE

Patient Identification

ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE.

PRE-MEDICATIONS: (Administer 30 minutes prior to infusion)

Note to provider: Please select which medications below, if any, you would like the patient to receive prior to treatment by checking the appropriate box(s)

- acetaminophen (TYLENOL) tablet, 650 mg, oral, ONCE, every visit
- loratadine (CLARITIN) tablet, 10 mg, oral, ONCE, every visit

MEDICATIONS (must check one):

- Actual body weight ≥ 30 kg: avalglucosidase alfa (NEXVIAZYME) 20 mg/kg in dextrose 5%, intravenous, ONCE, every 2 weeks
- Actual body weight < 30 kg: avalglucosidase alfa (NEXVIAZYME) 40 mg/kg in dextrose 5%, intravenous, ONCE, every 2 weeks

HYPERSENSITIVITY MEDICATIONS:

1. NURSING COMMUNICATION – If hypersensitivity or infusion reactions develop, temporarily hold the infusion and notify provider immediately. Administer emergency medications per the Treatment Algorithm for Acute Infusion Reaction (OHSU HC-PAT-133-GUD, HMC C-132). Refer to algorithm for symptom monitoring and continuously assess as grade of severity may progress.
2. diphenhydrAMINE (BENADRYL) injection, 25-50 mg, intravenous, AS NEEDED x 1 dose for hypersensitivity or infusion reaction
3. EPINEPHrine HCl (ADRENALIN) injection, 0.3 mg, intramuscular, AS NEEDED x 1 dose for hypersensitivity or infusion reaction
4. hydrocortisone sodium succinate (SOLU-CORTEF) injection, 100 mg, intravenous, AS NEEDED x 1 dose for hypersensitivity or infusion reaction
5. famotidine (PEPCID) injection, 20 mg, intravenous, AS NEEDED x 1 dose for hypersensitivity or infusion reaction

By signing below, I represent the following:

I am responsible for the care of the patient (*who is identified at the top of this form*);

I hold an active, unrestricted license to practice medicine in: Oregon _____ (*check box that corresponds with state where you provide care to patient and where you are currently licensed. Specify state if not Oregon*);

My physician license Number is # _____ (MUST BE COMPLETED TO BE A VALID PRESCRIPTION); and I am acting within my scope of practice and authorized by law to order Infusion of the medication described above for the patient identified on this form.

Provider signature: _____ Date/Time: _____

Printed Name: _____ Phone: _____ Fax: _____



**Oregon Health & Science University
Hospital and Clinics Provider's Orders**

ADULT AMBULATORY INFUSION ORDER
**Avalglucosidase Alfa
(NEXVIAZYME) Infusion**

Page 3 of 3

ACCOUNT NO.
MED. REC. NO.
NAME
BIRTHDATE

Patient Identification

ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE.

Central Intake:

Phone: 971-262-9645 (providers only) Fax: 503-346-8058

Please check the appropriate box for the patient's preferred clinic location:

Beaverton

OHSU Knight Cancer Institute
15700 SW Greystone Court
Beaverton, OR 97006

Phone number: 971-262-9000

Fax number: 503-346-8058

NW Portland

Legacy Good Samaritan campus
Medical Office Building 3, Suite 150
1130 NW 22nd Ave.
Portland, OR 97210

Phone number: 971-262-9600

Fax number: 503-346-8058

Gresham

Legacy Mount Hood campus
Medical Office Building 3, Suite 140
24988 SE Stark
Gresham, OR 97030

Phone number: 971-262-9500

Fax number: 503-346-8058

Tualatin

Legacy Meridian Park campus
Medical Office Building 2, Suite 140
19260 SW 65th Ave.
Tualatin, OR 97062

Phone number: 971-262-9700

Fax number: 503-346-8058

Infusion orders located at: www.ohsuknight.com/infusionorders